Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Abstract Background Semaglutide is a glucose-lowering treatment for type 2 diabetes (T2D) with demonstrated cardiovascular benefits; semaglutide may also have kidney-protective effects. This post hoc analysis investigated the association between major adverse cardiovascular events (MACE) and baselin...

Full description

Bibliographic Details
Main Authors: Peter Rossing, Stephen C. Bain, Heidrun Bosch-Traberg, Ekaterina Sokareva, Hiddo J. L. Heerspink, Søren Rasmussen, Linda G. Mellbin
Format: Article
Language:English
Published: BMC 2023-08-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Cardiovascular disease
Kidney disease
Glucagon-like peptide-1 receptor agonist
Semaglutide
Major cardiovascular events
Online Access:https://doi.org/10.1186/s12933-023-01949-7

Similar Items

Similar Items